Skip to main navigation
  • News & Investors

    News & Investors

    • Press Releases
    • Financial Events
    • Scientific Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Analyst Coverage
    • Request Information
    • Investor FAQs
    • Investor Contact
  • Contact Us
Celsion
  • TECHNOLOGY
    • LTSL
    • TheraPlas
    • TheraSilence
  • PRODUCTS
    • ThermoDox
    • GEN-1
  • PIPELINE
    • Clinical Studies
    • Pre-clinical Programs
  • DISEASES
  • PUBLICATIONS
  • ABOUT US
    • Leadership
    • Board of Directors
    • Corporate Governance
Select Page

Press Releases

    Investor Relations

    • News & Investors
    • Press Releases
    • Financial Events
    • Scientific Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Analyst Coverage
    • Request Information
    • Investor FAQs
    • Investor Contact

Press Releases

Company News

Date Title and Summary Additional Formats
Toggle Summary Apr 12, 2018 International Liver Congress™ 2018 Symposium Highlights Celsion’s ThermoDox® in Treatment of Primary Liver Cancer
   LAWRENCEVILLE, N.J. , April 12, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced a presentation and discussion of ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin in Phase III development for the
View HTML
PDF Version
Toggle Summary Apr 9, 2018 Data Monitoring Committee (DMC) Completes Planned Safety and Data Review of Celsion’s Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
DMC Unanimously Recommends Continuation of OPTIMA Study Based on Safety Data From 411 Patients; Enrollment Now at 80% Blinded Progression-Free Survival (PFS) Rate in the OPTIMA Study is Consistent With the Subgroup Patient Population That Showed Benefit in the HEAT Study ThermoDox®-Highlighted
View HTML
PDF Version
Toggle Summary Mar 27, 2018 Celsion Corporation Reports Fourth Quarter and Full-Year 2017 Financial Results
Celsion Enters 2018 with Solid Fundamentals, a Strong Balance Sheet and             an Advancing Clinical Pipeline Company to Hold Conference Call on Tuesday, March 27, 2018 at 11:00 a.m. EDT LAWRENCEVILLE, N.J. , March 27, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology
View HTML
PDF Version
Toggle Summary Mar 20, 2018 Celsion Corporation to Hold Year-End 2017 Financial Results Conference Call on Tuesday, March 27, 2018
LAWRENCEVILLE, N.J. , March 20, 2018 (GLOBE NEWSWIRE) --  Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the year ended December 31, 2017 and provide an update on its development programs for ThermoDox®, its
View HTML
PDF Version
Toggle Summary Mar 12, 2018 Celsion Corporation to Present at Upcoming Investor Conferences
Company to Discuss its Ongoing Pivotal Phase III and its Phase II Clinical Studies in Oncology    LAWRENCEVILLE, N.J. , March 12, 2018 (GLOBE NEWSWIRE) --  -- Celsion Corporation  (NASDAQ: CLSN), an oncology drug development company, today announced that Michael Tardugno , Chairman, President and
View HTML
PDF Version
Toggle Summary Mar 5, 2018 Celsion Announces Ovarian Cancer Expert Presentation at Oppenheimer & Co. Investor Event
Discussion Included Overview of Ovarian Cancer Treatment Landscape and Celsion’s Immunotherapy Product Candidate, GEN-1 Presentation Available on Celsion’s Website LAWRENCEVILLE, N.J. , March 05, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) today announced that Premal H.
View HTML
PDF Version
Toggle Summary Feb 12, 2018 Celsion Announces ThermoDox® HEAT Study Presentation at Korean Liver Cancer Association's 12th Annual Scientific Meeting
-Thesis Supporting the Phase III OPTIMA Study Chosen for the Presidential Selection Lecture by the Academic Committee - - Celsion to Host Symposium on Hepatocellular Carcinoma at International Liver Congress 2018 in April -
View HTML
Celsion Announces ThermoDox® HEAT Study Presentation at Korean Liver Cancer Association's 12th Annual Scientific Meeting 30.5 KB
Toggle Summary Jan 18, 2018 Celsion Corporation Provides Corporate Update and 2018 Outlook
Company Advances ThermoDox® for Treatment of Primary Liver Cancer Following Independent Data Monitoring Committee's Unanimous Recommendation to Continue Phase III OPTIMA Study OPTIMA Study Enrollment Reached 74% Enrollment at Year-End, With Enrollment Completion Expected in Third Quarter 2018
View HTML
Celsion Corporation Provides Corporate Update and 2018 Outlook 42.4 KB
Toggle Summary Jan 4, 2018 Celsion Announces FDA Clearance of the OVATION II Study for the Evaluation of GEN-1 Immunotherapy to Treat Newly Diagnosed Stage III/IV Ovarian Cancer
GEN-1 to Enter the Clinic in Mid-2018 Following a Phase IB Trial Which Demonstrated 100% Disease Control, 86% Objective Response Rate and 86% R0 & R1 Surgical Resection Rate in All Patients Treated Compelling Progression-Free Survival Data from Phase IB Trial Supports Development of GEN-1 as a
View HTML
Celsion Announces FDA Clearance of the OVATION II Study for the Evaluation of GEN-1 Immunotherapy to Treat Newly Diagnosed Stage III/IV Ovarian Cancer 26.8 KB
Toggle Summary Nov 20, 2017 Celsion Announces Publication of the Study of ThermoDox® + Ultrasound, "TARDOX Study Protocol" in the Journal of Therapeutic Ultrasound
Collaboration with University of Oxford to Execute a Clinical Trial Using Focused Ultrasound and ThermoDox® for Primary and Metastatic Liver Cancer Presentation of TARDOX Study Phase I Findings at the Upcoming RSNA 2017 Annual Meeting First Ever Study Evaluating ThermoDox® with Focused Ultrasound
View HTML
Celsion Announces Publication of the Study of ThermoDox® + Ultrasound, "TARDOX Study Protocol" in the Journal of Therapeutic Ultrasound 29.1 KB

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • …
  • Next page Next
  • Last page Last

    Shareholder Tools

    • Printed Materials
    • Email Alerts
    • Downloads
    • RSS
    • Print
    • Search

    • Facebook
    • Google
    • LinkedIn
    • Twitter
    • RSS

Home

Technology

Products

Pipeline

Disease

Publications

News & Investors

About Us

Careers

Privacy Policy

    ThermoDox is a registered trademark of Celsion Corporation.
    TheraPlas and TheraSilence are trademarks of Celsion Corporation.
    Avastin is a registered trademark of Genentech, Inc.
    Copyright © 2018 Celsion Corporation. All rights reserved.

    Share This
    • Twitter
    • Google+
    • Facebook
    • LinkedIn